prazosin has been researched along with Acute Confusional Senile Dementia in 7 studies
Prazosin: A selective adrenergic alpha-1 antagonist used in the treatment of HEART FAILURE; HYPERTENSION; PHEOCHROMOCYTOMA; RAYNAUD DISEASE; PROSTATIC HYPERTROPHY; and URINARY RETENTION.
prazosin : A member of the class of piperazines that is piperazine substituted by a furan-2-ylcarbonyl group and a 4-amino-6,7-dimethoxyquinazolin-2-yl group at positions 1 and 4 respectively.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Prazosin was well tolerated and improved behavioral symptoms in patients with agitation/aggression in AD." | 9.14 | Prazosin for the treatment of behavioral symptoms in patients with Alzheimer disease with agitation and aggression. ( Hart, KL; Hoff, DJ; McFall, YH; Peskind, ER; Raskind, MA; Rohde, K; Shofer, JB; Wang, LY, 2009) |
| "Prazosin was well tolerated and improved behavioral symptoms in patients with agitation/aggression in AD." | 5.14 | Prazosin for the treatment of behavioral symptoms in patients with Alzheimer disease with agitation and aggression. ( Hart, KL; Hoff, DJ; McFall, YH; Peskind, ER; Raskind, MA; Rohde, K; Shofer, JB; Wang, LY, 2009) |
| "In the hippocampal formation of Alzheimer's disease (AD) patients, both focal and diffuse deposits of Aβ peptides appear in a subregion- and layer-specific manner." | 1.37 | Glutaminyl cyclase contributes to the formation of focal and diffuse pyroglutamate (pGlu)-Aβ deposits in hippocampus via distinct cellular mechanisms. ( Cynis, H; Demuth, HU; Hartlage-Rübsamen, M; Jäger, C; Koch, B; Morawski, M; Rossner, S; Schilling, S; Schliebs, R; Waniek, A; Zeitschel, U, 2011) |
| "[3H]Prazosin binding was highest in the hippocampus and frontal cortex and lowest in the caudate and putamen in the control brains." | 1.27 | Biochemical characterization of alpha-adrenergic receptors in human brain and changes in Alzheimer-type dementia. ( Fujiwara, M; Kameyama, M; Shimohama, S; Taniguchi, T, 1986) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (28.57) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (42.86) | 29.6817 |
| 2010's | 2 (28.57) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Wang, LY | 1 |
| Shofer, JB | 1 |
| Rohde, K | 1 |
| Hart, KL | 1 |
| Hoff, DJ | 1 |
| McFall, YH | 1 |
| Raskind, MA | 2 |
| Peskind, ER | 2 |
| Hartlage-Rübsamen, M | 1 |
| Morawski, M | 1 |
| Waniek, A | 1 |
| Jäger, C | 1 |
| Zeitschel, U | 1 |
| Koch, B | 1 |
| Cynis, H | 1 |
| Schilling, S | 1 |
| Schliebs, R | 1 |
| Demuth, HU | 1 |
| Rossner, S | 1 |
| Katsouri, L | 1 |
| Vizcaychipi, MP | 1 |
| McArthur, S | 1 |
| Harrison, I | 1 |
| Suárez-Calvet, M | 1 |
| Lleo, A | 1 |
| Lloyd, DG | 1 |
| Ma, D | 1 |
| Sastre, M | 1 |
| Szot, P | 1 |
| White, SS | 1 |
| Greenup, JL | 1 |
| Leverenz, JB | 1 |
| Sharp, SI | 1 |
| Ballard, CG | 1 |
| Chen, CP | 1 |
| Francis, PT | 1 |
| O'Neill, C | 1 |
| Fowler, CJ | 1 |
| Winblad, B | 1 |
| Shimohama, S | 1 |
| Taniguchi, T | 1 |
| Fujiwara, M | 1 |
| Kameyama, M | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Alzheimer's in Long-Term Care--Treatment for Agitation[NCT00161473] | 24 participants (Actual) | Interventional | 2001-01-31 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
"The Brief Psychiatric Rating Scale (BPRS) is an 18-item scale that rates psychiatric symptoms. Each item ranges from 1 to 7. Therefore, the Brief Psychiatric Rating Scale total score ranges from a minimum of 0 to a maximum of 126, where 126 indicates higher levels of behavioral symptoms.~A change Brief Psychiatric Rating Scale score that is a negative number (that is, a Brief Psychiatric Rating Scale score decrease), indicates behavioral improvement." (NCT00161473)
Timeframe: Weeks 2, 4, 6, and 8 (change from Baseline)
| Intervention | units on a scale (Mean) |
|---|---|
| Prazosin | -9 |
| Placebo | -3 |
"The Neuropsychiatric Inventory (NPI) is a 12-item scale that assesses the frequency and severity of behavioral symptoms in patients with dementia. Each Neuropsychiatric Inventory item ranges from 0 to 12. Therefore the Neuropsychiatric Inventory total score has a minimum total value of 0 and maximum 144, where 144 indicates higher levels of behavioral symptoms.~A change in Neuropsychiatric Inventory total score that is a negative number (that is, an Neuropsychiatric Inventory score decrease), indicates behavioral improvement." (NCT00161473)
Timeframe: Weeks 2, 4, 6, and 8 (change from Baseline)
| Intervention | units on a scale (Mean) |
|---|---|
| Prazosin | -19 |
| Placebo | -2 |
"The Clinical Global Impression of Change (CGIC) is a 7 point scale, where 1 indicates markedly improved, 4 indicates no change, and 7 indicates markedly worse." (NCT00161473)
Timeframe: Week 8
| Intervention | units on a scale (Mean) |
|---|---|
| Prazosin | 2.6 |
| Placebo | 4.5 |
This measure reflects the length of time participants remained in the study. There were 6 behavioral assessment visits included in the protocol. (NCT00161473)
Timeframe: Last behavioral assessment (Baseline, Weeks 1, 2, 4, 6, or 8)
| Intervention | number of visits (Mean) |
|---|---|
| Prazosin | 4.8 |
| Placebo | 4.5 |
1 trial available for prazosin and Acute Confusional Senile Dementia
| Article | Year |
|---|---|
Prazosin for the treatment of behavioral symptoms in patients with Alzheimer disease with agitation and aggression.
Topics: Adrenergic alpha-Antagonists; Aged; Aged, 80 and over; Aggression; Alzheimer Disease; Behavioral Sym | 2009 |
6 other studies available for prazosin and Acute Confusional Senile Dementia
| Article | Year |
|---|---|
Glutaminyl cyclase contributes to the formation of focal and diffuse pyroglutamate (pGlu)-Aβ deposits in hippocampus via distinct cellular mechanisms.
Topics: Adrenergic alpha-1 Receptor Antagonists; Adrenergic alpha-2 Receptor Antagonists; Adrenergic beta-An | 2011 |
Prazosin, an α(1)-adrenoceptor antagonist, prevents memory deterioration in the APP23 transgenic mouse model of Alzheimer's disease.
Topics: Adrenergic alpha-1 Receptor Antagonists; Alzheimer Disease; Amyloid beta-Peptides; Animals; Disease | 2013 |
Compensatory changes in the noradrenergic nervous system in the locus ceruleus and hippocampus of postmortem subjects with Alzheimer's disease and dementia with Lewy bodies.
Topics: Adrenergic alpha-Antagonists; Adult; Aged; Aged, 80 and over; Alzheimer Disease; Dendrites; Female; | 2006 |
Aggressive behavior and neuroleptic medication are associated with increased number of alpha1-adrenoceptors in patients with Alzheimer disease.
Topics: Aggression; Alzheimer Disease; Antipsychotic Agents; Binding Sites; Cell Count; Cerebellum; Frontal | 2007 |
Alpha 1-adrenergic receptor binding sites in post-mortal human cerebral microvessel preparations: preservation in multi-infarct dementia and dementia of Alzheimer type.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Cerebral Cortex; Cerebrovascular Circulation; Clonidine; | 1989 |
Biochemical characterization of alpha-adrenergic receptors in human brain and changes in Alzheimer-type dementia.
Topics: Aged; Alzheimer Disease; Binding, Competitive; Brain; Cell Membrane; Cerebellum; Female; Hippocampus | 1986 |